ChromaDex Corporation reiterated earnings guidance for the full year of 2024. For the full year, the company expects the trajectory of full year revenue growth to continue, projecting a higher rate of revenue growth than the prior year growth of 16%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.73 USD | +3.02% | 0.00% | +90.91% |
25/06 | ChromaDex Chief Financial Officer Brianna Gerber to Resign | MT |
24/06 | ChromaDex Says Nicotinamide Riboside Shows 'Promising Effects' in Peripheral Artery Disease Trial | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+90.91% | 207M | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
+10.74% | 25.92B | |
-13.50% | 26.03B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B | |
-12.61% | 10.64B |
- Stock Market
- Equities
- CDXC Stock
- News ChromaDex Corporation
- ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024